UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of clinical oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 32, pp. 4017 - 4025
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Tumors | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Thiazoles - blood | Injections, Intravenous | Area Under Curve | Pyrimidines - blood | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Half-Life | Thiazoles - administration & dosage | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Drug Monitoring - methods | Indoles - administration & dosage | Antibodies, Monoclonal - blood | Antibodies, Monoclonal, Humanized | Neoplasms - blood | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Benzenesulfonates - blood | Antineoplastic Agents - pharmacokinetics | Cetuximab | Piperazines - blood | Everolimus | Molecular Targeted Therapy - methods | Dasatinib | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Indoles - blood | Rituximab | Pyrroles - blood | Sirolimus - blood | Evidence-Based Medicine | Imatinib Mesylate | Neoplasms - drug therapy | Sirolimus - administration & dosage | Antibodies, Monoclonal, Murine-Derived - blood | Pyridines - blood | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - blood | Benzamides | Index Medicus
Journal Article
Cancer letters, ISSN 0304-3835, 2012, Volume 320, Issue 1, pp. 104 - 110
Hematology, Oncology and Palliative Medicine | Combination index | Dasatinib | Molecular targeted therapy | Rapamycin | Life Sciences & Biomedicine | Oncology | Science & Technology | Niacinamide - analogs & derivatives | Paclitaxel - pharmacology | Nitriles - pharmacology | Humans | Epothilones - pharmacology | Thiazoles - administration & dosage | Chromones - administration & dosage | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Tamoxifen - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Benzenesulfonates - pharmacology | Female | Chromones - pharmacology | Paclitaxel - administration & dosage | Butadienes - pharmacology | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Morpholines - pharmacology | Pyrimidines - pharmacology | Breast Neoplasms - drug therapy | Sirolimus - pharmacology | Drug Synergism | Sirolimus - administration & dosage | Signal Transduction - drug effects | Butadienes - administration & dosage | Epothilones - administration & dosage | Tamoxifen - pharmacology | Cell Line, Tumor | Pyridines - pharmacology | Thiazoles - pharmacology | Care and treatment | Oncology, Experimental | Genes | Breast cancer | Research | Tamoxifen | Cancer | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 13, pp. 2280 - 2285
Life Sciences & Biomedicine | Oncology | Science & Technology | Cardiology. Vascular system | Biological and medical sciences | Medical sciences | Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous | Blood and lymphatic vessels | Tumors | Niacinamide - analogs & derivatives | Thromboembolism - chemically induced | Humans | Middle Aged | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Thromboembolism - epidemiology | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Incidence | Angiogenesis Inhibitors - administration & dosage | Pyridines - adverse effects | Pyrroles - administration & dosage | Pyrroles - adverse effects | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Angiogenesis Inhibitors - adverse effects | Arterial Occlusive Diseases - chemically induced | Pyridines - administration & dosage | Risk Assessment | Administration, Oral | Risk Factors | Arterial Occlusive Diseases - epidemiology | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Aged | Index Medicus
Journal Article
The oncologist (Dayton, Ohio), ISSN 1083-7159, 10/2008, Volume 13, Issue 10, pp. 1084 - 1096
Dosing | Temsirolimus | Sunitinib | Safety | Renal cell carcinoma | Sorafenib | Life Sciences & Biomedicine | Oncology | Science & Technology | Niacinamide - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Recombinant Proteins | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Bevacizumab | Antibodies, Monoclonal, Humanized | Pyridines - adverse effects | Pyrroles - administration & dosage | Pyrroles - adverse effects | Carcinoma, Renal Cell - drug therapy | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Carcinoma, Renal Cell - pathology | Interferon-alpha - administration & dosage | Sirolimus - administration & dosage | Indoles - adverse effects | Antibodies, Monoclonal - administration & dosage | Kidney Neoplasms - pathology | Interferon-alpha - adverse effects | Kidney Neoplasms - drug therapy | Index Medicus
Journal Article
Journal of medicinal chemistry, ISSN 0022-2623, 08/2020, Volume 63, Issue 15, pp. 8512 - 8523
Prodrugs - administration & dosage | Glutathione - metabolism | Bibenzyls - pharmacokinetics | Humans | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Photochemotherapy | Indoles - administration & dosage | Drug Delivery Systems | Photosensitizing Agents - administration & dosage | Benzenesulfonates - pharmacokinetics | Benzenesulfonates - pharmacology | Photosensitizing Agents - pharmacology | Indoles - pharmacology | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Bibenzyls - administration & dosage | HCT116 Cells | Organometallic Compounds - pharmacokinetics | Hep G2 Cells | Neoplasms - drug therapy | Prodrugs - pharmacokinetics | Photosensitizing Agents - pharmacokinetics | Indoles - pharmacokinetics | Bibenzyls - pharmacology | Prodrugs - pharmacology | Organometallic Compounds - pharmacology | Organometallic Compounds - administration & dosage | Index Medicus
Journal Article
International journal of pharmaceutics, ISSN 0378-5173, 2011, Volume 419, Issue 1, pp. 339 - 346
Suspension | Oral bioavailability | pH-sensitive nanoparticles | Nanomatrix | Sorafenib | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Pharmaceutical technology. Pharmaceutical industry | Biological and medical sciences | Medical sciences | General pharmacology | Pharmacology. Drug treatments | Niacinamide - analogs & derivatives | Pyridines - administration & dosage | Administration, Oral | Area Under Curve | Adhesiveness | Silicon Dioxide - chemistry | Solubility | Pyridines - pharmacokinetics | Rats | Biological Availability | Male | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Nanostructures | Polymethacrylic Acids - chemistry | Rats, Sprague-Dawley | Nanoparticles | Benzenesulfonates - pharmacokinetics | Animals | Antineoplastic Agents - pharmacokinetics | Porosity | Suspensions | Hydrogen-Ion Concentration | Antimitotic agents | Antineoplastic agents | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 08/2008, Volume 26, Issue 22, pp. 3709 - 3714
Biological and medical sciences | Medical sciences | Tumors | Niacinamide - analogs & derivatives | raf Kinases - antagonists & inhibitors | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Antibodies, Monoclonal, Humanized | Angiogenesis Inhibitors - administration & dosage | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Ovarian Neoplasms - drug therapy | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Vascular Endothelial Growth Factor A - blood | Neoplasms - enzymology | Treatment Outcome | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Neoplasm Staging | Neoplasms - pathology | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 09/2006, Volume 24, Issue 26, pp. 4293 - 4300
Gastroenterology. Liver. Pancreas. Abdomen | Biological and medical sciences | Medical sciences | Liver. Biliary tract. Portal circulation. Exocrine pancreas | Tumors | Niacinamide - analogs & derivatives | Predictive Value of Tests | Extracellular Signal-Regulated MAP Kinases - blood | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Protein Kinase Inhibitors - adverse effects | RNA, Neoplasm - blood | Benzenesulfonates - adverse effects | Liver Neoplasms - blood | Benzenesulfonates - pharmacokinetics | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Carcinoma, Hepatocellular - genetics | Aged, 80 and over | Adult | Female | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacokinetics | Carcinoma, Hepatocellular - blood | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Drug Administration Schedule | Liver Neoplasms - genetics | Liver Neoplasms - drug therapy | Treatment Outcome | Biomarkers, Tumor - blood | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Neoplasm Staging | Index Medicus
Journal Article
Clinical cancer research, ISSN 1078-0432, 06/2017, Volume 23, Issue 11, pp. 2730 - 2741
ANTIBODIES | INDOCYANINE GREEN | IN-111-BEVACIZUMAB | ANGIOGENESIS | SAFETY | CONSERVING SURGERY | MARGINS | OVARIAN-CANCER | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Life Sciences & Biomedicine | Oncology | Science & Technology | Optical Imaging | Bevacizumab - adverse effects | Humans | Male | Positron-Emission Tomography | Benzenesulfonates - administration & dosage | Vascular Endothelial Growth Factor A - genetics | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Drug-Related Side Effects and Adverse Reactions - pathology | Feasibility Studies | Antibodies, Monoclonal, Humanized - administration & dosage | Breast Neoplasms, Male - diagnostic imaging | Female | Breast Neoplasms - diagnostic imaging | Antibodies, Monoclonal, Humanized - adverse effects | Breast Neoplasms, Male - diagnosis | Tissue Distribution - drug effects | Bevacizumab - administration & dosage | Breast Neoplasms, Male - drug therapy | Breast Neoplasms - drug therapy | Indoles - adverse effects | Breast Neoplasms - pathology | Cell Line, Tumor | Breast Neoplasms - diagnosis | Breast Neoplasms, Male - pathology | Multiplexing | Drug delivery systems | Intravenous administration | Invasiveness | Feasibility studies | Fluorescence | I.R. radiation | Breast cancer | Patients | Bevacizumab | Surgical instruments | Histopathology | Microscopy | Experimental design | Surgery | In vivo methods and tests | Safety | Vascular endothelial growth factor | Cancer | Index Medicus
Journal Article
10.
Full Text
Advanced-stage hepatocellular carcinoma: Transarterial chemoembolization versus sorafenib
Radiology, ISSN 0033-8419, 2012, Volume 263, Issue 2, pp. 590 - 599
Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Liver Neoplasms - therapy | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Ethiodized Oil - adverse effects | Benzenesulfonates - adverse effects | Chemoembolization, Therapeutic - methods | Ethiodized Oil - administration & dosage | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Contrast Media - administration & dosage | Adult | Female | Liver Neoplasms - pathology | Retrospective Studies | Doxorubicin - administration & dosage | Pyridines - administration & dosage | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Chi-Square Distribution | Disease Progression | Magnetic Resonance Imaging | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Carcinoma, Hepatocellular - therapy | Neoplasm Staging | Doxorubicin - adverse effects | Index Medicus | Abridged Index Medicus
Journal Article
British journal of dermatology (1951), ISSN 0007-0963, 11/2009, Volume 161, Issue 5, pp. 1045 - 1051
sunitinib | sorafenib | cutaneous adverse effects | Cutaneous adverse effects | Sunitinib | Sorafenib | Life Sciences & Biomedicine | Dermatology | Science & Technology | Biological and medical sciences | Medical sciences | Niacinamide - analogs & derivatives | Humans | Middle Aged | Hand Dermatoses - chemically induced | Male | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Skin Diseases - pathology | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Young Adult | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Aged, 80 and over | Pyrroles - adverse effects | Adult | Female | Retrospective Studies | Carcinoma, Renal Cell - drug therapy | Drug Eruptions - etiology | Skin Diseases - chemically induced | Pyridines - administration & dosage | Administration, Oral | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Stomatitis - chemically induced | Foot Dermatoses - chemically induced | Alopecia - chemically induced | Aged | Kidney Neoplasms - drug therapy | Antimitotic agents | Complications and side effects | Liver cancer | Medical colleges | Care and treatment | Antineoplastic agents | Tumors | Index Medicus
Journal Article